GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.15
Bid: 40.00
Ask: 40.45
Change: 3.00 (8.08%)
Spread: 0.45 (1.125%)
Open: 37.95
High: 40.80
Low: 37.95
Prev. Close: 37.15
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Futura Regains Ownership of CSD500

28 Aug 2012 07:00

RNS Number : 7968K
Futura Medical PLC
28 August 2012
 



For immediate release

28 August 2012

 

 

Futura Medical plc

("Futura" or "the Company")

Futura Regains Ownership of CSD500

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that Futura and Reckitt Benckiser have been unable to reach a common ground acceptable to both parties in respect of their continued development and commercialisation of the CSD500 condom leading to a mutual agreement to terminate their commercial relationship.

Futura intends to partner CSD500 with one or more of the world's other leading condom or healthcare companies. Futura has received considerable interest from such companies and formal discussions will now commence.

In order to get CSD500 to market as quickly as possible Futura will take control of the manufacturing of the product and apply directly for a CE Mark. Manufacturing will be outsourced to a third party manufacturer for onward supply of finished condoms to commercial partners. To this end, development work with an independent contract condom manufacturer has already commenced. The manufacturer already has the necessary ISO 13485 certification for the manufacture of condoms with ancillary medicinal substances. 

Futura has ownership rights over all previous clinical data generated for the original approved dossier and therefore does not anticipate the need for any new clinical data. Futura expects to submit a new CE Mark dossier in the first half of 2013 to the regulatory authorities that approved CSD500 last year.

Futura has also regained worldwide ownership of MED2002, the Company's topical gel for the treatment of erectile dysfunction, which was also licensed to Reckitt Benckiser.

James Barder, Futura's Chief Executive, commented: "Futura has received considerable interest in CSD500 from potential marketing partners. We are therefore confident of relicensing the product on attractive commercial terms and of creating significant value for shareholders."

 

For any further information please contact:

 

Futura Medical plc

 

James Barder, Chief Executive

 

Tel: +44 (0)1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

 

 

 

Nomura Code Securities Limited

 

Phil Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

 

 

 

For media enquiries please contact:

 

 

 

Buchanan

 

Mark Court / Fiona Henson / Sophie Cowles

Tel: +44 (0)20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBKQDKABKDNFB
Date   Source Headline
24th Nov 20171:08 pmRNSBlock Listing Update
23rd Oct 20173:30 pmRNSPDMR Dealing
16th Oct 20177:00 amRNSFurther Positive Market Research Data for MED2002
13th Sep 20177:00 amRNSDirectors' / PDMR Dealing and Grant of Options
12th Sep 20177:00 amRNSInterim Results
1st Sep 201712:24 pmRNSNotification of Major Interest in Shares
23rd Aug 201710:32 amRNSCSD500: Termination of Licensing Agreement
22nd Aug 20173:59 pmRNSNotification of Half Year Results
4th Jul 20177:00 amRNSInvestor Presentation on MED2002
14th Jun 20175:00 pmRNSResult of AGM
14th Jun 20177:00 amRNSAGM Statement
31st May 20177:00 amRNSMED2002 Regulatory Update
31st May 20177:00 amRNSTotal Voting Rights
22nd May 20177:00 amRNSBlock Listing Update
20th Apr 20179:45 amRNSNotice of AGM
4th Apr 201712:11 pmRNSNotification of Major Interest in Shares
4th Apr 201712:10 pmRNSNotification of Major Interest in Shares
23rd Mar 20177:00 amRNSPreliminary Results
22nd Mar 20177:00 amRNSLicenses CSD500 in Portugal
6th Mar 20177:00 amRNSResearch Confirms MED2002's US$1 Billion Potential
6th Mar 20177:00 amRNSMED2002 Additional Patent Filing
23rd Jan 20171:00 pmRNSNotice of Preliminary Results
18th Jan 20174:30 pmRNSDirector's dealings
13th Jan 20175:45 pmRNSDirector / PDMR Dealing and Grant of Options
12th Jan 20173:00 pmRNSDirector / PDMR Dealing and Total Voting Rights
11th Jan 201712:20 pmRNSDirector's Dealings
10th Jan 201712:40 pmRNSNED Remuneration and Total Voting Rights
10th Jan 20177:00 amRNSSigns UK Licensing Agreement in Pain Relief
5th Jan 20177:00 amRNSInitial Launch of CSD500 in MENA
28th Nov 20165:30 pmRNSCorrection: Notification of Major Interests
28th Nov 201612:00 pmRNSNotification of Major Interest in Shares
25th Nov 20165:25 pmRNSCorrection - Block Listing Update
25th Nov 20163:05 pmRNSBlock Listing Update
25th Nov 20169:30 amRNSNotification Of Major Interest In Shares
23rd Nov 20163:30 pmRNSNotification of Major Interest in Shares
16th Nov 20167:00 amRNSKen James to lead Futura's R&D
16th Nov 20167:00 amRNSMED2002 Update
15th Nov 20163:38 pmRNSResult of General Meeting
27th Oct 201612:45 pmRNSResult of Placing
27th Oct 20169:48 amRNSClose of Accelerated Bookbuild
27th Oct 20167:01 amRNSProposed Accelerated Bookbuild
27th Oct 20167:00 amRNSCSD500: Approval of TTK with Extended Shelf Life
13th Sep 20167:00 amRNSInterim Results
12th Sep 20165:45 pmRNSNotification of Major Interest in Shares
12th Sep 20163:00 pmRNSNotification of Major Interest in Shares
7th Sep 20167:00 amRNSMED2002: Breakthrough Results in $5 billion Market
25th Jul 20167:00 amRNSNotification of Half Year Results
21st Jun 20165:30 pmRNSResult of AGM
21st Jun 20167:00 amRNSAGM Statement
20th Jun 20167:00 amRNSLicenses CSD500 to Milsing for Southeast Europe

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.